{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~10 mi. (Valenciennes, France, +226 more cities)
facility
Centre Hospitalier de Valenciennes ( Site 0439)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~10 mi. (Valenciennes, France, +158 more cities)
facility
Clinique Teissier Groupe ( Site 0808)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~14 mi. (Bruyelle, Belgium, +199 more cities)
facility
Erasme Hospital ( Site 0376)
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~14 mi. (Bruyelle, Belgium, +163 more cities)
facility
UCL Saint-Luc - Oncologie Medicale ( Site 0357)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~21 mi. (Mons, Belgium, +176 more cities)
facility
C.I.U. Hopital Ambroise Pare ( Site 2039)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~21 mi. (Mons, Belgium, +147 more cities)
facility
C.I.U. Hopital Ambroise Pare ( Site 0353)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~21 mi. (Mons, Belgium, +122 more cities)
facility
C.I.U. Hopital Ambroise Pare ( Site 1001)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~35 mi. (Lille, France, +93 more cities)
facility
Polyclinique du Bois ( Site 0458)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~35 mi. (Lille, France, +207 more cities)
facility
Centre Oscar Lambret ( Site 0911)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types